Eli Lilly to Pull Cancer Drug From Market After Failed Study

Eli Lilly & Co. said Thursday it plans to withdraw its cancer drug Lartruvo from the market after a study showed that it failed to prolong overall survival in a clinical trial.

The company will establish an access program to allow some patients with soft-tissue sarcoma—a cancer that develops in connective tissue including muscle—to continue taking the drug with limited interruption after it’s withdrawn from the market. Lilly didn’t provide a specific timeline and said it’s working with health regulators on its plans.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJ /  🏆 98. in ZA

South Africa South Africa Latest News, South Africa South Africa Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Stock market fails to extend climb to records as energy-sector retreat weighsThe S&P 500 and the Nasdaq Composite indexes on Wednesday failed to extend their climb into record territory as a pullback in the mostly buoyant energy...
Read more »